[Our experience in the treatment of superficial cancer of the bladder with BCG].
We report on our experience with 21 patients with superficial bladder cancer who were treated with intravesical BCG instillation. The BCG vaccine was effective in the treatment of carcinoma in situ. Tumor regression was achieved in 83.3% at 3 months, and 61.1% at 24 months. It is advisable to follow patients closely because of the possibility of tumor progression.
E
E
Martínez
I
I
Díaz
J
J
Salvador
J M
JM
Viladoms
E
E
Zungri
F J
FJ
Solé-Balcells
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine
Nuestra experiencia en el tratamiento del cáncer superficial de vejiga con BCG.